Resources

Support for you and your patients with IBS-D

The resources below include information about dosing, insurance requirements,* and the science behind XIFAXAN. You’ll also find materials to share with your patients to help them understand treatment with XIFAXAN and keep track of their IBS-D symptoms.

*Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

For your practice

An overview of key clinical information about IBS-D and treatment with XIFAXAN.

Keep easy-to-follow directions on hand to help make PA submissions simple for XIFAXAN. Includes both IBS-D and OHE indications.

A Tier Exemption Request to reduce the cost-share of a medication. Follows submission of a PA or Utilization Management request.

A summary of dosing information for prescribing XIFAXAN.

A standard form for a patientā€specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.

Learn how QSA can support your patients and practice.

Get perspectives from your peers, tools, and educational material on diagnosis and treatment of IBS-D.

For your patients

Keep patients informed about what it means to have and treat IBS-D with XIFAXAN.

Help patients identify possible symptoms of IBS-D.

Help your patients start the conversation about their IBS-D symptoms.

Card Copay Card

Instant Savings Card

Available for eligible, commercially insured patients.

DOWNLOAD OR ACTIVATE NOW

Patient is not eligible if he/she participates in, seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full-cash–paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com or call 1-866-XIFAXAN for full eligibility criteria, terms, and conditions.

Video Library

Watch Dr. Brenner explain the importance of recognizing and treating multiple symptoms of IBS-D

Watch Dr. Cash discuss the inclusion of XIFAXAN for IBS-D in the American College of Gastroenterology’s 2020 Clinical Guideline on managing IBS

Watch Dr. Pimentel and Dr. Brenner present information on the gut microbiota and IBS-D

See why Dr. Pimentel, Dr. Brenner, and Joscelyn Greaves, MSN, APRN-CNP, think XIFAXAN FIRST

Watch Dr. Sayuk discuss IBS-D and treatment with XIFAXAN

Watch Dr. Pimentel discuss XIFAXAN dosing

Watch Dr. Chang explain the role of dysbiosis in the pathophysiology of IBS-D

Watch a patient discuss the impact of IBS-D and see her reaction to hearing Dr. Oneto describe XIFAXAN for the first time

Watch Dr. Pimentel, Dr. Brenner, and Joscelyn Greaves, MSN, APRN-CNP, discuss different approaches used to manage IBS-D symptoms

Watch this video explanation of how XIFAXAN is believed to work

Watch Dr. Moussa discuss diagnosing IBS-D and treating with XIFAXAN

Watch Dr. Pimentel discuss his approach to IBS-D diagnosis

Watch as Clinical Pharmacy Specialist, Ralph Riello, walks you through best practices to help with Xifaxan PA success.

HE, hepatic encephalopathy; IBS-D, irritable bowel syndrome with diarrhea; MOA, mechanism of action; OHE, overt hepatic encephalopathy; PCP, primary care physician.

See More

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
See Less

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
    IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

XIFI.0127.USA.23V2.0